Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study
Abstract Background Idiopathic pulmonary fibrosis (IPF) is frequently accompanied by comorbidities, with the management of these comorbidities crucial for clinical outcomes. This study investigated the prevalence, incidence, changes over time, and clinical impact of comorbidities in IPF patients, ba...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-023-02340-8 |
| _version_ | 1811171859995033600 |
|---|---|
| author | Jang Ho Lee Hyung Jun Park Seonok Kim Ye-Jee Kim Ho Cheol Kim |
| author_facet | Jang Ho Lee Hyung Jun Park Seonok Kim Ye-Jee Kim Ho Cheol Kim |
| author_sort | Jang Ho Lee |
| collection | DOAJ |
| description | Abstract Background Idiopathic pulmonary fibrosis (IPF) is frequently accompanied by comorbidities, with the management of these comorbidities crucial for clinical outcomes. This study investigated the prevalence, incidence, changes over time, and clinical impact of comorbidities in IPF patients, based on nationwide claims data in South Korea. Methods This retrospective cohort study utilised nationwide health claim data in South Korea between 2011 and 2019. Patients with IPF were defined as those with ICD-10 code J84.1 and Rare Intractable Disease code V236 who made at least one claim per year. Patients were classified by sex, age, pirfenidone use and burden of comorbidities, and differences among groups were determined. Results The yearly prevalence rate of IPF increased from 7.50 to 23.20 per 100,000 people, and the yearly incidence rate increased from 3.56 to 7.91 per 100,000 person-years over time. The most common respiratory comorbidity was chronic obstructive pulmonary disease (37.34%), followed by lung cancer (3.34%), whereas the most common non-respiratory comorbidities were gastro-oesophageal reflux disease (70.83%), dyslipidaemia (62.93%) and hypertension (59.04%). The proportion of some comorbidities differed by sex, age and use of pirfenidone. The proportion of lung cancer was higher in patients treated with pirfenidone, whereas the proportion of anxiety and depression were lower in patients not treated with pirfenidone. Charlson comorbidity index ≥ 4 was associated with increases in hospitalisations and total medical costs. Conclusions The yearly prevalence and incidence of IPF and comorbidities in Korea increased over time. These comorbidities affected the use of pirfenidone and medical resources. |
| first_indexed | 2024-04-10T17:21:13Z |
| format | Article |
| id | doaj.art-0ca3b124e6794c25b5098f66ea23aab9 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-04-10T17:21:13Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-0ca3b124e6794c25b5098f66ea23aab92023-02-05T12:03:42ZengBMCBMC Pulmonary Medicine1471-24662023-02-0123111010.1186/s12890-023-02340-8Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort studyJang Ho Lee0Hyung Jun Park1Seonok Kim2Ye-Jee Kim3Ho Cheol Kim4Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Centre, University of Ulsan College of MedicineDivision of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Centre, University of Ulsan College of MedicineDepartment of Clinical Epidemiology and Biostatistics, Asan Medical Centre, University of Ulsan College of MedicineDepartment of Clinical Epidemiology and Biostatistics, Asan Medical Centre, University of Ulsan College of MedicineDivision of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Centre, University of Ulsan College of MedicineAbstract Background Idiopathic pulmonary fibrosis (IPF) is frequently accompanied by comorbidities, with the management of these comorbidities crucial for clinical outcomes. This study investigated the prevalence, incidence, changes over time, and clinical impact of comorbidities in IPF patients, based on nationwide claims data in South Korea. Methods This retrospective cohort study utilised nationwide health claim data in South Korea between 2011 and 2019. Patients with IPF were defined as those with ICD-10 code J84.1 and Rare Intractable Disease code V236 who made at least one claim per year. Patients were classified by sex, age, pirfenidone use and burden of comorbidities, and differences among groups were determined. Results The yearly prevalence rate of IPF increased from 7.50 to 23.20 per 100,000 people, and the yearly incidence rate increased from 3.56 to 7.91 per 100,000 person-years over time. The most common respiratory comorbidity was chronic obstructive pulmonary disease (37.34%), followed by lung cancer (3.34%), whereas the most common non-respiratory comorbidities were gastro-oesophageal reflux disease (70.83%), dyslipidaemia (62.93%) and hypertension (59.04%). The proportion of some comorbidities differed by sex, age and use of pirfenidone. The proportion of lung cancer was higher in patients treated with pirfenidone, whereas the proportion of anxiety and depression were lower in patients not treated with pirfenidone. Charlson comorbidity index ≥ 4 was associated with increases in hospitalisations and total medical costs. Conclusions The yearly prevalence and incidence of IPF and comorbidities in Korea increased over time. These comorbidities affected the use of pirfenidone and medical resources.https://doi.org/10.1186/s12890-023-02340-8ComorbidityIdiopathic pulmonary fibrosisIncidencePirfenidonePrevalence |
| spellingShingle | Jang Ho Lee Hyung Jun Park Seonok Kim Ye-Jee Kim Ho Cheol Kim Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study BMC Pulmonary Medicine Comorbidity Idiopathic pulmonary fibrosis Incidence Pirfenidone Prevalence |
| title | Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study |
| title_full | Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study |
| title_fullStr | Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study |
| title_full_unstemmed | Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study |
| title_short | Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study |
| title_sort | epidemiology and comorbidities in idiopathic pulmonary fibrosis a nationwide cohort study |
| topic | Comorbidity Idiopathic pulmonary fibrosis Incidence Pirfenidone Prevalence |
| url | https://doi.org/10.1186/s12890-023-02340-8 |
| work_keys_str_mv | AT jangholee epidemiologyandcomorbiditiesinidiopathicpulmonaryfibrosisanationwidecohortstudy AT hyungjunpark epidemiologyandcomorbiditiesinidiopathicpulmonaryfibrosisanationwidecohortstudy AT seonokkim epidemiologyandcomorbiditiesinidiopathicpulmonaryfibrosisanationwidecohortstudy AT yejeekim epidemiologyandcomorbiditiesinidiopathicpulmonaryfibrosisanationwidecohortstudy AT hocheolkim epidemiologyandcomorbiditiesinidiopathicpulmonaryfibrosisanationwidecohortstudy |